Drug intelligence / Profile preview

Liqi Shuxin

Development stage: Unknown
Lead developer: Jilin Fukang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Liqi Shuxin is a traditional Chinese medicine (TCM) formulation developed and manufactured by Jilin Fukang Pharmaceutical. It is primarily administered as an oral tablet and is indicated for conditions associated with 'Qi stagnation' and 'blood stasis' in TCM terminology. These conditions often manifest as chest tightness, oppression, abdominal distension, and psychosomatic symptoms related to emotional distress or digestive discomfort. The formulation aims to regulate the flow of Qi and soothe the heart and chest area. As a complex herbal mixture, its therapeutic effects are derived from the synergistic actions of multiple botanical components rather than a single molecular target. It is currently approved and marketed in China.

Brand names: Liqi Shuxin Pian理气舒心片
Other names: Liqi Shuxin Tablets

Beyond the preview

Go deeper on Liqi Shuxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liqi Shuxin.

Explore the full profile